Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 614-618

  Ikeda, Fumiaki ^a   Wakai, Yoshimi ^a   Matsumoto, Satoru ^a   Maki, Katsuyuki ^a   Watabe, Etsuko ^a   Tawara, Shuichi ^a   Goto, Toshio ^a   Watanabe, Yuji ^a   Matsumoto, Fumio ^b   Kuwahara, Shogo ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b Kanagawa Pref Nursing Hygienic S   (Japan)

^c TOHO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; FLUCONAZOLE; HYDROCORTISONE; LIPOPEPTIDE; MICAFUNGIN;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BACTERIOSTASIS; CANDIDA; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FUNGUS GROWTH; IMMUNE DEFICIENCY; KIDNEY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; IMMUNOSUPPRESSION; KIDNEY; LIPOPROTEINS; MALE; MICE; MICE, INBRED ICR; PEPTIDES, CYCLIC;

EID: 17744404136     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.614-618.2000     Document Type: Article

References (18)

1. Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41: 2333-2338.
2. Anaisse, E., G. P. Bodey, H. Kantarjian, J. Ro, S. E. Vartivarian, R. Hopfer, J. Hoy, and K. Polston. 1989. New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. 11:369-378.
3. Anaisse, E., G. P. Bodey, and M. G. Rinaldi. 1989. Emerging fungal pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 8:323-330.
4. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, W. J. Martone, and the National Nosocomial Infections Surveillance System. 1991. Secular trends in nosocomial primary bloodstream infections in the United States. Am. J. Med. 91(Suppl. 3B):86S-89S.
5. Bartnicki-Garcia, S. 1968. Cell wall chemistry, morphogenesis, and taxonomy of fungi. Annu. Rev. Microbiol. 22:87-108.
6. Beck-Sague, C. M., W. R. Jarvis, and the National Nosocomial Infections Surveillance System. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
7. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
8. Hitchcock, C. A., G. W. Pye, D. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
9. Ingroff, A. E. 1998. Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
10. Kim, H., D. Loebenberg, A. Marco, S. Symchowicz, and C. Lin. 1984. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys. Antimicrob. Agents Chemother. 26:446-449.
11. Louie, A., G. L. Drusano, P. Banerjee, Q. Liu, W. Liu, P. Kaw, M. Shayegani, H. Taber, and M. H. Miller. 1998. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. 42: 1105-1109.
12. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42:2726-2730.
13. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
14. Poeta, M. D., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41:1835-1836.
15. Ruhnke, M., A. Eigler, I. Tennagen, B. Geiseler, E. Engelmann, and M. Trautmann. 1994. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
16. Thomas, A. H. 1986. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J. Antimicrob. Chemother. 17:269-279.
17. Verweiji, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
18. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kobani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.